Ero Copper Corp (ERO)vsSanofi ADR (SNY)
ERO
Ero Copper Corp
$28.48
+5.09%
BASIC MATERIALS · Cap: $2.83B
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 5025% more annual revenue ($47.35B vs $923.93M). ERO leads profitability with a 31.6% profit margin vs 16.0%. ERO trades at a lower P/E of 9.7x. ERO earns a higher WallStSmart Score of 78/100 (B+).
ERO
Strong Buy78
out of 100
Grade: B+
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+7.2%
Fair Value
$33.93
Current Price
$28.48
$5.45 discount
Margin of Safety
+25.0%
Fair Value
$62.70
Current Price
$43.31
$19.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 33 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 34.7%
Revenue surging 110.4% year-over-year
Reasonable price relative to book value
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
No major concerns identified
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ERO
The strongest argument for ERO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 31.6% and operating margin at 34.7%. Revenue growth of 110.4% demonstrates continued momentum.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : ERO
No major red flags identified for ERO, but monitor valuation.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ERO profiles as a growth stock while SNY is a mature play — different risk/reward profiles.
ERO carries more volatility with a beta of 1.56 — expect wider price swings.
ERO is growing revenue faster at 110.4% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
ERO scores higher overall (78/100 vs 51/100), backed by strong 31.6% margins and 110.4% revenue growth. SNY offers better value entry with a 25.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ero Copper Corp
BASIC MATERIALS · COPPER · USA
Ero Copper Corp. The company is headquartered in Vancouver, Canada.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other COPPER Stocks
Want to dig deeper into these stocks?